AMEX:PTN (USA) Also trade in: Germany UK

Palatin Technologies Inc

$ 1.42 0.02 (1.43%)
On watch
Volume: 2,340,385 Avg Vol (1m): 1,703,988
Market Cap $: 288.35 Mil Enterprise Value $: 269.87 Mil
P/E (TTM): 0.00 P/B: 18.21
Earnings Power Value -10.62
Net Current Asset Value 0.08
Tangible Book 0.08
Projected FCF -0.54
Median P/S Value 0.63
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 14.91
Cash-To-Debt ranked lower than
50.57% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
PTN: 14.91
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.48, Med: 71.87, Max: 10000
Current: 14.91
0.48
10000
Debt-to-Equity 0.08
Debt-to-Equity ranked lower than
81.71% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
PTN: 0.08
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -4.19, Med: 0.02, Max: 6.67
Current: 0.08
-4.19
6.67
Debt-to-EBITDA -0.36
Debt-to-EBITDA ranked higher than
78.45% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
PTN: -0.36
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.34, Med: -0.02, Max: 0.24
Current: -0.36
-1.34
0.24
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 13.37
DISTRESS
GREY
SAFE
Beneish M-Score -3.81
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 16.9%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -14.09
Operating Margin ranked higher than
96.69% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
PTN: -14.09
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -155850, Med: -98.89, Max: 38.62
Current: -14.09
-155850
38.62
Net Margin % -15.68
Net Margin ranked higher than
97.93% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
PTN: -15.68
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -208620, Med: -89.35, Max: 36.8
Current: -15.68
-208620
36.8
ROE % -23.32
ROE ranked lower than
100.00% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
PTN: -23.32
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -172.33, Med: -95.26, Max: 226.63
Current: -23.32
-172.33
226.63
ROA % -15.85
ROA ranked higher than
99.24% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
PTN: -15.85
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -256.44, Med: -75.2, Max: 51.55
Current: -15.85
-256.44
51.55
ROC (Joel Greenblatt) % -2409.33
ROC (Joel Greenblatt) ranked higher than
99.61% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
PTN: -2409.33
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -44524.89, Med: -4689.35, Max: 14495.58
Current: -2409.33
-44524.89
14495.58
3-Year Total Revenue Growth Rate 73.10
3-Year Revenue Growth Rate ranked lower than
100.00% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
PTN: 44.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -30.6, Max: 276.8
Current: 44.7
0
276.8

» PTN's 30-Y Financials

Financials (Next Earnings Date: 2019-09-13)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with AMEX:PTN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 325412    SIC : 2834
Compare TSE:4595 NAS:CTSO NAS:CELC NYSE:ARA ASX:VHT TSX:AKU.U XMAD:CBAV TSE:2309 XKRX:245620 HKSE:08037 XKRX:038290 LSE:EKF ISX:PRDA MEX:MEDICA B NAS:STIM NYSE:ENZ TSE:6678 ASX:IDX TSE:4978 XPAR:LBIRD
Traded in other countries PTNA.Germany 0KF3.UK
Address 4-B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Ratios

Current vs industry vs history
PB Ratio 18.21
PB Ratio ranked lower than
94.29% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
PTN: 18.21
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.72, Med: 2.34, Max: 30.3
Current: 18.21
0.72
30.3
PS Ratio 15.08
PS Ratio ranked higher than
69.13% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
PTN: 15.08
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.85, Med: 6.71, Max: 1440
Current: 15.08
0.85
1440
EV-to-EBIT -72.52
EV-to-EBIT ranked higher than
96.61% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
PTN: -72.52
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -84.54, Med: -1.3, Max: 100.5
Current: -72.52
-84.54
100.5
EV-to-EBITDA -73.70
EV-to-EBITDA ranked higher than
93.94% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
PTN: -73.7
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -85.88, Med: -1.3, Max: 96.9
Current: -73.7
-85.88
96.9
EV-to-Revenue 9.11
EV-to-Revenue ranked higher than
76.86% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
PTN: 9.11
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -1.7, Med: 5.4, Max: 2618.1
Current: 9.11
-1.7
2618.1
Current Ratio 4.15
Current Ratio ranked lower than
71.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
PTN: 4.15
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.55, Med: 3.58, Max: 21.07
Current: 4.15
0.55
21.07
Quick Ratio 4.15
Quick Ratio ranked lower than
66.40% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
PTN: 4.15
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.55, Med: 3.58, Max: 21.07
Current: 4.15
0.55
21.07

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -52.00
3-Year Share Buyback Rate ranked lower than
87.22% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
PTN: -52
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -114.5, Med: -37.3, Max: 0
Current: -52
-114.5
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 17.75
Price-to-Tangible-Book ranked lower than
87.92% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
PTN: 17.75
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.74, Med: 4.44, Max: 159.41
Current: 17.75
0.74
159.41
Price-to-Median-PS-Value 2.25
Price-to-Median-PS-Value ranked higher than
91.71% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
PTN: 2.25
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.16, Med: 1.32, Max: 69
Current: 2.25
0.16
69
Earnings Yield (Joel Greenblatt) % -1.38
Earnings Yield (Greenblatt) ranked higher than
98.49% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
PTN: -1.38
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -10817.8, Med: -38.3, Max: 99662.8
Current: -1.38
-10817.8
99662.8

More Statistics

Revenue (TTM) (Mil) $ 29.62
EPS (TTM) $ -0.03
Beta 2.43
Volatility % 58.33
52-Week Range $ 0.59 - 1.74
Shares Outstanding (Mil) 203.06

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N